Qiao Yeqiong

本報北京電(記者王美華)3月24日，我國首個自主研發的新型結核病mRNA疫苗在首都醫科大學附屬北京胸科醫院啟動臨床試驗，首批納入36名研究參與者接種疫苗，該院副院長李亮作為首位研究參與者接種了疫苗。

"I've been waiting for this moment for too many years!" As a clinician who has been engaged in tuberculosis diagnosis and treatment for more than 30 years, Li Liang has always been very concerned about the research trend of mRNA vaccines, "I am very fortunate to be the first research participant in this vaccine research experiment, I am very confident in this vaccine, and I hope that in the near future, it can become a major tool to end tuberculosis." ”

As one of the oldest infectious diseases in the world, tuberculosis still threatens human health today. Currently, BCG vaccine, the only approved TB vaccine in the world, can prevent severe TB in infants and young children, but it has limited protection against adolescents and adults. The development of an effective TB vaccine for adolescents and adults has become an urgent challenge for researchers around the world.

"In recent years, mRNA vaccines have become new stars in the field of vaccine research and development due to their significant advantages such as high safety and strong ability to induce specific immune responses." According to Xiao Yu, the person in charge of vaccine research and development and the director of the Department of Bacterial Immunology of Beijing Chest Hospital, the team has gone through a lot of hard and meticulous work to select 3 dominant antigens from more than 0 candidate antigens metabolized by Mycobacterium tuberculosis in multiple pathways and combine them, and finally successfully screened 0 combinations with the best protective effect.

動物實驗顯示，該新型mRNA疫苗的保護效力較卡介苗提高了20倍以上，展現出巨大潛力。“若一切順利，這款具有自主知識產權的結核病mRNA疫苗有望實現臨床上市。”逄宇介紹，屆時將惠及超過3億結核潛伏感染者和1億結核病感染風險人群，並計劃推廣至全人群接種，將有效降低結核病發病率和感染率，控制結核病傳播。

In addition to the mRNA vaccine, Beijing Chest Hospital also released the tuberculosis tongue swab detection technology, the AI intelligent diagnosis model based on acoustic biomarkers, the new anti-tuberculosis drug and the 9-month treatment of drug-resistant tuberculosis with bedaquiline.